Cite
Del Campo M, Galimberti D, Elias N, et al. Novel CSF biomarkers to discriminate FTLD and its pathological subtypes. Ann Clin Transl Neurol. 2018;5(10):1163-1175doi: 10.1002/acn3.629.
Del Campo, M., Galimberti, D., Elias, N., Boonkamp, L., Pijnenburg, Y. A., van Swieten, J. C., Watts, K., Paciotti, S., Beccari, T., Hu, W., & Teunissen, C. E. (2018). Novel CSF biomarkers to discriminate FTLD and its pathological subtypes. Annals of clinical and translational neurology, 5(10), 1163-1175. https://doi.org/10.1002/acn3.629
Del Campo, Marta, et al. "Novel CSF biomarkers to discriminate FTLD and its pathological subtypes." Annals of clinical and translational neurology vol. 5,10 (2018): 1163-1175. doi: https://doi.org/10.1002/acn3.629
Del Campo M, Galimberti D, Elias N, Boonkamp L, Pijnenburg YA, van Swieten JC, Watts K, Paciotti S, Beccari T, Hu W, Teunissen CE. Novel CSF biomarkers to discriminate FTLD and its pathological subtypes. Ann Clin Transl Neurol. 2018 Sep 07;5(10):1163-1175. doi: 10.1002/acn3.629. eCollection 2018 Oct. PMID: 30349851; PMCID: PMC6186934.
Copy
Download .nbib